Eli Lilly and (LLY) | Stock Overview & Key Data
Eli Lilly and Performance Comparison
Stock Range
Today's Range
Low: $748.00
High: $761.60
on September 12, 2025
52 Week Range
Low: $623.78
High: $942.35
on August 8, 2025
on September 13, 2024
All-Time High: $972.53 on August 19, 2024
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$691.8B
EPS
15.33
P/E Ratio (TTM)
49.28
Forward P/E
33.34
P/B Ratio
37.07
PEG Ratio
0.54
Div. Yield
0.52%
ROE
86.29%
Beta
0.465
Debt to Equity
217.89
Financial Highlights
Profitability
Gross Margin
84.27%
Operating Margin
45.81%
Profit Margin
25.91%
Returns and Earnings
Return on Assets (TTM)
16.55%
Return on Equity (TTM)
86.29%
EBITDA
$24.8B
Net Income (TTM)
$13.8B
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$59.34
Quarterly Revenue Growth (YoY)
37.60%
Quarterly Earnings Growth (YoY)
90.80%
Dividend Information
Last 12-Month Dividend
$4.10
Current Dividend Yield
0.52%
3-Year Average Dividend Yield
0.22%
3-Year Average Annual Dividend
$4.02
3-Year Total Dividends
$12.05
Ex-Dividend Date
February 14, 2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Eli Lilly and LLY | 691.79B Mega-cap | 3.88% | 18.13% | -6.98% | -8.09% | -2.91% | -18.22% | 144.55% | 389.97% |
| Johnson & Johnson JNJ | 428.83B Mega-cap | -0.21% | 3.06% | 13.66% | 9.34% | 23.64% | 7.58% | 6.24% | 19.36% |
| AbbVie ABBV | 385.71B Mega-cap | 2.72% | 9.92% | 13.47% | 2.96% | 21.68% | 12.41% | 51.55% | 142.28% |
| Merck & Co MRK | 206.84B Mega-cap | -2.24% | 3.13% | 1.21% | -11.29% | -16.50% | -28.53% | -5.60% | 1.14% |
| Amgen AMGN | 148.80B Large-cap | -2.56% | -3.01% | -7.03% | -11.56% | 6.60% | -16.83% | 19.62% | 11.61% |
| Gilead Sciences GILD | 142.13B Large-cap | -0.43% | -4.56% | 2.23% | 0.49% | 24.67% | 38.33% | 74.62% | 76.10% |
Ownership & Short Interest
Insider Ownership
0.16%
Institutional Ownership
83.86%
Shares Short
8M
Short Ratio
1.22
Short % of Shares Outstanding
1.01%
Average 10-Day Volume
3M
Average 90-Day Volume
6M
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is LLY's 52-week high and low?
- In the last 52 weeks, Eli Lilly and reached a high of $942.35 (on September 13, 2024) and a low of $623.78 (on August 8, 2025).
- What is the market cap and P/E ratio for LLY?
- Curious about Eli Lilly and's size and valuation? Its market capitalization stands at 691.79B. When it comes to valuation, the P/E ratio (trailing twelve months) is 49.28, and the forward P/E (looking ahead) is 33.34.
- Does LLY pay dividends? If so, what's the yield?
- Yes, Eli Lilly and is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 0.52%, and the company has paid an average of $4.02 per share annually over the past 3 years.
- Who are Eli Lilly and's main competitors or similar companies to consider before investing?
When looking at Eli Lilly and, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Johnson & Johnson
JNJ428.83B Healthcare Drug Manufacturers - General 7.58% 6.24% AbbVie
ABBV385.71B Healthcare Drug Manufacturers - General 12.41% 51.55% Merck & Co
MRK206.84B Healthcare Drug Manufacturers - General -28.53% -5.60% Amgen
AMGN148.80B Healthcare Drug Manufacturers - General -16.83% 19.62% Gilead Sciences
GILD142.13B Healthcare Drug Manufacturers - General 38.33% 74.62% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Eli Lilly and Company? (e.g., ROE, Debt/Equity)
- To get a sense of Eli Lilly and's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 86.29%, the Debt to Equity ratio from the most recent quarter is 217.89, and its Gross Profit Margin stands at 84.27%.
- What is the recent revenue and earnings growth for LLY?
- Looking at Eli Lilly and's growth, its revenue over the trailing twelve months (TTM) was $53B. Compared to the same quarter last year (YoY), quarterly revenue grew by 37.60%, and quarterly earnings saw a YoY growth of 90.80%.
- How much of LLY stock is held by insiders and institutions?
- Wondering who owns Eli Lilly and stock? Company insiders (like executives and directors) hold about 0.16% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 83.86%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.